This site is intended only for healthcare professionals resident in Egypt

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information

Menu

Close

Burden of Disease Prevenar 13® Effectiveness Dosing Risk Prevention Important Safety Information Abbreviated Prescribing Information
Burden of DiseasePneumococcal disease remains the leading cause of vaccine-preventable death in children worldwide.2Clinical manifestations of pneumococcal disease include:
  The WHO recommends including PCVs in childhood immunization programmes.7 *Based on the 2011 surveillance of notifiable disease cases among children <5 years of age reported to the Centers for Disease Control and Prevention. Policies for reporting notifiable disease cases can vary by disease or reporting jurisdiction.3Abbreviations:

AIDS, acquired immune deficiency syndrome; IPD, invasive pneumococcal disease; OM, otitis media; PCV, pneumococcal conjugate vaccine; WHO, World Health Organization.

References:
  1. Egyptian drug authority Prevenar 13 leaflet approval date 7/4/2021, revision date November 2020.
  2. World Health Organization. Immunisation Coverage. Accessed April 4, 2023. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage.
  3. Centers for Disease Control and Prevention. Summary of Notifiable Diseases, United States, 2011. MMWR Morb Mortal Wkly Rep. 2013;60(53):1-117.
  4. Grijalva CG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369(9568):1179-1186.
  5. Zhou F, et al. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med. 2007;161(12):1162-1168.
  6. Rodgers GL, et al. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine. 2009;27(29):3802-3810.
  7. World Health Organization. Wkly Epidemiol Rec. 2012;87(14):129-144.

Explore More

Effectiveness in Pneumonia
 Learn MoreLoading
Broad Coverage
 Learn moreLoading
Dosing
 Learn moreLoading
Prevenar 13® Prescribing Information Loading
PP-PRV-EGY-0027

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


PP-UNP-EGY-0241
For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 

If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
 

I confirm that I am a healthcare professional resident in Egypt.
 

PP-UNP-EGY-0241

Yes No
You are leaving the Pfizer for Professionals website
​You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.
 
PP-UNP-EGY-0241
You are leaving the Pfizer for Professionals website You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.

PP-UNP-EGY-0241